Quality-of-life impairment in depressive and anxiety disorders

被引:683
作者
Rapaport, MH
Clary, C
Fayyad, R
Endicott, J
机构
[1] Cedars Sinai Med Ctr, Dept Psychiat, Thalians Mental Hlth Ctr C301, Los Angeles, CA 90048 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA
[3] Pfizer Inc, New York, NY USA
[4] Columbia Univ, Coll Phys & Surg, New York, NY USA
关键词
D O I
10.1176/appi.ajp.162.6.1171
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Previous reports demonstrating quality-of-life impairment in anxiety and affective disorders have relied upon epidemiological samples or relatively small clinical studies. Administration of the same quality-of-life scale, the Quality of Life Enjoyment and Satisfaction Questionnaire, to subjects entering multiple large-scale trials for depression and anxiety disorders allowed us to compare the impact of these disorders on quality of life. Method: Baseline Quality of Life Enjoyment and Satisfaction Questionnaire, demographic, and clinical data from 11 treatment trials, including studies of major depressive disorder, chronic/double depression, dysthymic disorder, panic disorder, obsessive-compulsive disorder (OCD), social phobia, premenstrual dysphoric disorder, and posttraumatic stress disorder (PTSD) were analyzed. Results: The proportion of patients with clinically severe impairment ( two or more standard deviations below the community norm) in quality of life varied with different diagnoses: major depressive disorder (63%), chronic/double depression (85%), dysthymic disorder (56%), panic disorder (20%), OCD (26%), social phobia (21%), premenstrual dysphoric disorder (31%), and PTSD (59%). Regression analyses conducted for each disorder suggested that illness-specific symptom scales were significantly associated with baseline quality of life but explained only a small to modest proportion of the variance in Quality of Life Enjoyment and Satisfaction Questionnaire scores. Conclusions: Subjects with affective or anxiety disorders who enter clinical trials have significant quality-of-life impairment, although the degree of dysfunction varies. Diagnostic-specific symptom measures explained only a small proportion of the variance in quality of life, suggesting that an individual's perception of quality of life is an additional factor that should be part of a complete assessment.
引用
收藏
页码:1171 / 1178
页数:8
相关论文
共 55 条
[31]  
Litz, 1994, PTSD RES Q, V5, P2, DOI DOI 10.1037/E572192010-003
[32]   A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression [J].
Lydiard, RB ;
Stahl, SM ;
Hertzman, M ;
Harrison, WM .
JOURNAL OF CLINICAL PSYCHIATRY, 1997, 58 (11) :484-491
[33]   Quality of life in individuals with anxiety disorders [J].
Mendlowicz, MV ;
Stein, MB .
AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (05) :669-682
[34]  
Olfson M, 1996, ARCH GEN PSYCHIAT, V53, P880
[35]   Mental disorders and disability among patients in a primary care group practice [J].
Olfson, M ;
Fireman, B ;
Weissman, MM ;
Leon, AC ;
Sheehan, DV ;
Kathol, RG ;
Hoven, C ;
Farber, L .
AMERICAN JOURNAL OF PSYCHIATRY, 1997, 154 (12) :1734-1740
[36]  
Patrick D. L., 1988, CLIN NUTR, V7, P53
[37]  
Pyne JM, 1997, PSYCHOPHARMACOL BULL, V33, P23
[38]  
Rapaport MH, 1998, PSYCHOPHARMACOL BULL, V34, P183
[39]   Quality of well being in panic disorder: the assessment of psychiatric and general disability [J].
Rubin, HC ;
Rapaport, MH ;
Levine, B ;
Gladsjo, JK ;
Rabin, A ;
Auerbach, M ;
Judd, LL ;
Kaplan, R .
JOURNAL OF AFFECTIVE DISORDERS, 2000, 57 (1-3) :217-221
[40]  
Safren SA., 1997, DEPRESS ANXIETY, V4, P126, DOI [DOI 10.1002/(SICI)1520-6394(1996)4:3LT